SanegeneBio announced a global licensing agreement with Genentech on February 2, 2026, granting exclusive worldwide rights to one of its proprietary RNAi programs.12
SanegeneBio receives $200 million upfront payment and is eligible for up to $1.5 billion in development and commercialization milestones, plus tiered royalties.123
SanegeneBio handles early development; Genentech leads subsequent clinical development and global commercialization.14
The RNAi program leverages SanegeneBio's proprietary platform with novel chemistries and delivery technologies; specific target and indication undisclosed.12
Quote from SanegeneBio CEO Weimin Wang:
'Entering into this agreement with Genentech marks another important milestone for our innovative and differentiated RNAi chemistry and delivery platforms.'14
Sources:
1. https://www.prnewswire.com/news-releases/sanegenebio-announces-rnai-global-licensing-collaboration-with-genentech-302676224.html
2. https://www.biopharminternational.com/view/genentech-expands-rnai-pipeline-through-global-licensing-deal
3. https://www.genengnews.com/topics/drug-discovery/genentech-sanegenebio-launch-up-to-1-7b-rnai-collaboration/
4. https://www.fiercebiotech.com/biotech/roches-return-rna-continues-17b-deal-sanegene-program